LSV Asset Management Sells 155,119 Shares of Puma Biotechnology, Inc. $PBYI

LSV Asset Management trimmed its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 27.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 404,802 shares of the biopharmaceutical company’s stock after selling 155,119 shares during the period. LSV Asset Management owned about 0.80% of Puma Biotechnology worth $2,409,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. ProShare Advisors LLC bought a new position in Puma Biotechnology during the 4th quarter worth about $60,000. Williams & Novak LLC bought a new position in Puma Biotechnology during the 4th quarter worth about $63,000. D Orazio & Associates Inc. grew its holdings in Puma Biotechnology by 56.0% during the 4th quarter. D Orazio & Associates Inc. now owns 49,807 shares of the biopharmaceutical company’s stock worth $296,000 after acquiring an additional 17,874 shares in the last quarter. One Wealth Advisors LLC bought a new position in Puma Biotechnology during the 4th quarter worth about $115,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Puma Biotechnology during the 4th quarter worth about $49,000. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Price Performance

Shares of PBYI opened at $7.27 on Wednesday. The company’s fifty day moving average price is $7.00 and its 200-day moving average price is $6.36. Puma Biotechnology, Inc. has a 1-year low of $3.03 and a 1-year high of $7.90. The firm has a market capitalization of $370.04 million, a PE ratio of 15.15 and a beta of 1.24.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.09. Puma Biotechnology had a return on equity of 20.30% and a net margin of 10.69%.The firm had revenue of $44.81 million for the quarter, compared to the consensus estimate of $42.00 million. As a group, research analysts anticipate that Puma Biotechnology, Inc. will post 0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on PBYI shares. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings cut shares of Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.